

EPI-001 & EPI-008

Differentiated cell therapy assets for hair regeneration

Hair.I. uncovers scalp microenvironment biology and fibroimmune remodeling to identify new regenerative therapies.

Apr 2026

EPI-001 Phase 1

Cohort 1 completed dosing in 3 subjects

2H 2026

EPI-001

Topline expected

2H 2026

EPI-008

IND submission

LEAD ASSET

EPI-001

Autologous Dermal Papilla Cell Therapy

First-in-Class Fibroimmune Remodeling Approach

INDICATION

Androgenetic alopecia (AGA)

MECHANISM

Modulates fibroimmune crosstalk in the scalp microenvironment to restore hair follicle regeneration

STAGE

Phase 1/2a in volunteers (EPI-001)

STRATEGIC VALUE

First-in-class approach unlocking a new regenerative pathway

EPI-008

Allogeneic / Off-the-Shelf Dermal Papilla Cell Therapy

Follow-on Scalable Asset

INDICATION

Androgenetic alopecia (AGA)

MECHANISM

Modulates fibroimmune crosstalk in the scalp microenvironment to promote hair follicle regeneration

STAGE

IND planning in 2H 2026 (EPI-008)

STRATEGIC VALUE

Allogeneic, off-the-shelf cell therapy with broad scalability and patient access potential

EPI-001 Preclinical Mouse Data

Control

0.25x10⁴/cm²

0.25x10⁵/cm²

2% Minoxidil

Day 3

Day 9

Day 11

Day 14

Day 16

50

40

30

20

10

0

Hair weight (mg)

Control

0.25 x 10⁴/cm²

0.25 x 10⁵/cm²

2% Minoxidil

Control

0.25 x 10⁴/cm²

0.25 x 10⁵/cm²

2% Minoxidil

Day-1

Day-9

Day-11

Day-13

Day-15

Day-17

0.8

0.7

0.6

0.5

0.4

0.3

0.2

0.1

0.0

Skin color score

Control

0.25 x 10⁴/cm²

0.25 x 10⁵/cm²

2% Minoxidil